These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29164637)

  • 21. Sample size re-estimation in group-sequential response-adaptive clinical trials.
    Morgan CC
    Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Realization of simulations for blinded internal pilot study based on web.
    Wang S; Xia J; Yu L; Li C; Xu L; Zheng L
    J Biomed Inform; 2009 Apr; 42(2):262-71. PubMed ID: 18775797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statistical tests with accurate size and power for balanced linear mixed models.
    Muller KE; Edwards LJ; Simpson SL; Taylor DJ
    Stat Med; 2007 Aug; 26(19):3639-60. PubMed ID: 17394132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sample size recalculation using conditional power.
    Denne JS
    Stat Med; 2001 Sep 15-30; 20(17-18):2645-60. PubMed ID: 11523074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re-calculating the sample size in internal pilot study designs with control of the type I error rate.
    Kieser M; Friede T
    Stat Med; 2000 Apr; 19(7):901-11. PubMed ID: 10750058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sample size calculation and re-estimation based on the prevalence in a single-arm confirmatory diagnostic accuracy study.
    Stark M; Zapf A
    Stat Methods Med Res; 2020 Oct; 29(10):2958-2971. PubMed ID: 32299298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blinded sample size re-estimation in three-arm trials with 'gold standard' design.
    Mütze T; Friede T
    Stat Med; 2017 Oct; 36(23):3636-3653. PubMed ID: 28608469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sample size recalculation based on the prevalence in a randomized test-treatment study.
    Hot A; Benda N; Bossuyt PM; Gerke O; Vach W; Zapf A
    BMC Med Res Methodol; 2022 Jul; 22(1):205. PubMed ID: 35879675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sample sizes required to detect two-way and three-way interactions involving slope differences in mixed-effects linear models.
    Heo M; Leon AC
    J Biopharm Stat; 2010 Jul; 20(4):787-802. PubMed ID: 20496206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blinded sample size reestimation in non-inferiority trials with binary endpoints.
    Friede T; Mitchell C; Müller-Velten G
    Biom J; 2007 Dec; 49(6):903-16. PubMed ID: 17726715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sample size re-estimation in cluster randomization trials.
    Lake S; Kammann E; Klar N; Betensky R
    Stat Med; 2002 May; 21(10):1337-50. PubMed ID: 12185888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re-evaluating design specifications of longitudinal clinical trials without unblinding when the key response is rate of change.
    Shih WJ; Gould AL
    Stat Med; 1995 Oct; 14(20):2239-48. PubMed ID: 8552900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Robustness of a parametric model for informatively censored bivariate longitudinal data under misspecification of its distributional assumptions: A simulation study.
    Pantazis N; Touloumi G
    Stat Med; 2007 Dec; 26(30):5473-85. PubMed ID: 18058854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blinded sample size reestimation with count data: methods and applications in multiple sclerosis.
    Friede T; Schmidli H
    Stat Med; 2010 May; 29(10):1145-56. PubMed ID: 20146203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study.
    Teare MD; Dimairo M; Shephard N; Hayman A; Whitehead A; Walters SJ
    Trials; 2014 Jul; 15():264. PubMed ID: 24993581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Power and Sample Size for Fixed-Effects Inference in Reversible Linear Mixed Models.
    Chi YY; Glueck DH; Muller KE
    Am Stat; 2019; 73(4):350-359. PubMed ID: 32042203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Power and sample size analysis for longitudinal mixed models of health in populations exposed to environmental contaminants: a tutorial.
    Harrall KK; Muller KE; Starling AP; Dabelea D; Barton KE; Adgate JL; Glueck DH
    BMC Med Res Methodol; 2023 Jan; 23(1):12. PubMed ID: 36635621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trials.
    Reichmann WM; LaValley MP; Gagnon DR; Losina E
    BMC Med Res Methodol; 2013 Feb; 13():21. PubMed ID: 23414513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re-estimating sample size in cluster randomised trials with active recruitment within clusters.
    van Schie S; Moerbeek M
    Stat Med; 2014 Aug; 33(19):3253-68. PubMed ID: 24719285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.